Passive and active drug delivery are two distinct approaches used to improve the targeted delivery of drugs within the body.

Endothelin receptor antagonists (ERAs) are drugs that block endothelin receptors, used to treat conditions like pulmonary arterial hypertension and Raynaud’s phenomenon.

Drug interactions occur when two or more medications are taken together and the effect is different than if they were taken separately.

Elpiscience has partnered with Astellas Pharma through a fresh research and licensing deal to develop innovative dual-targeting macrophage engagers.

The combination of dietary supplements and drugs should be approached with caution, as interactions between them can affect the efficacy and safety of both substances.

NMDA receptor antagonists are drugs that block NMDA receptors, aiding in the treatment of conditions such as chronic pain, epilepsy, depression, and schizophrenia.

By specifically targeting the affected cells or tissues, the drug can be delivered directly to the site of action, increasing its effectiveness while minimizing side effects on healthy cells.

Cytokinetics Reveals Encouraging Outcomes in Key Phase 3 Study Called SEQUOIA-HCM, Evaluating Aficamten for Obstructive Hypertrophic Heart Condition.

Drug antigenicity refers to the ability of a drug to stimulate an immune response in an individual due to its chemical structure.

CCR5 antagonists are drugs that target the CCR5 receptor, used in treating conditions like HIV infections.

Pharmaceutical patents are legal rights granted to inventors or companies that provide exclusive rights to produce and sell their innovation for a specified time.

Oncternal Therapeutics has released new information regarding its ongoing early to mid-stage clinical trial of ONCT-808, a CAR T therapy aimed at ROR1, for individuals facing recurring or hard-to-treat aggressive B-cell lymphoma.